Wockhardt Ltd — Earnings Release 2025

May 29, 2025

Ref. No.: WOCK/SEC/SE/2025-26/011

==> picture [182 x 50] intentionally omitted <==

29[th] May, 2025

BSE Limited Corporate Relations Department P J Towers Dalal Street Mumbai - 400 001 Scrip Code: 532300		National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai - 400 051 NSE Symbol: WOCKPHARMA

Dear Sir/ Madam,

Subject: Submission pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") - Press Release

Pursuant to Regulation 30 of Listing Regulations, please find enclosed Press Release on the Audited Financial Results (Standalone and Consolidated) for the quarter and the financial year ended 31[st] March, 2025.

A copy of the same will also be uploaded on the Company’s website www.wockhardt.com

Kindly take the same on record please.

Thanking you,

For Wockhardt Limited

Rashmi Digitally signed by Rashmi Dinesh Dinesh Mamtura Date: 2025.05.29 Mamtura 17:24:30 +05'30' Rashmi Mamtura Company Secretary

Encls: A/a

==> picture [510 x 32] intentionally omitted <==

Wockhardt Limited Registered Office: D-4, MIDC, Chikalthana Chhatrapati Sambhajinagar 431006, India Tel.: +91-22-2653 4444 CIN: L24230MH1999PLC120720

==> picture [143 x 30] intentionally omitted <==

==> picture [178 x 53] intentionally omitted <==

Mumbai, May 29[th] , 2025

• Wockhardt FY 25 EBITDA jumps to Rs.418 crore; growth by 67%

• Zaynich: Filed for approval in India in March 2025 and planned for filing in USA by August 2025

o Miqnaf approved and launched on May 27,2025 in India

Wockhardt Limited, the Pharmaceutical and Biotechnology major, reported its 4[th] Quarter Results for Financial Year 2024-25, today.

==> picture [182 x 93] intentionally omitted <==

YoY growth of 5% in revenue in FY25, Revenue for FY25 of INR 3,033 Cr compared to INR 2,879 Cr in the previous year. YoY growth of 67% in EBITDA in FY25, EBITDA for FY25 of INR 418 Cr compared to INR 251 Cr in the previous year.

Revenue for Q4FY25 of INR 743 Cr compared to INR 750 Cr in the previous year. QoQ growth of 13% in EBITDA in Q4FY25, EBITDA for Q4FY25 of INR 79 Cr compared to INR 70 Cr in the previous year.

Novel Antibiotics:

ZAYNICH® (Zidebactam/Cefepime, WCK 5222) Filed for approval in India in March 2025 and planned for filing in USA by August 2025

==> picture [403 x 49] intentionally omitted <==

Following the completion of the Global, pivotal, registration-enabling, Phase III study in hospitalized complicated urinary tract infection (cUTI) patients, Wockhardt’s Zaynich® has demonstrated the highest-ever efficacy achieving a clinical cure rate of 96.8%.

The study enrolled 529 patients with complicated urinary tract infection (cUTI) and Acute Pyelonephritis (AP) and was conducted in US, Europe, LATAM, China, India, spanning 64 sites.

In this study, Zaynich® demonstrated superiority over gold standard meropenem, achieving a composite clinical and microbiology cure rate of 89.0% vs 68.4% respectively. These results were based on primary endpoints defined by both the US FDA and EMA.

Wockhardt Limited Registered Office: D-4, MIDC, Chikalthana Chhatrapati Sambhajinagar 431006, India Tel.: +91-22-2653 4444 CIN: L24230MH1999PLC120720

==> picture [143 x 30] intentionally omitted <==

==> picture [178 x 53] intentionally omitted <==

The combined efficacy of Zaynich® is the highest ever recorded among recently approved novel antibiotics developed in more than a decade. The outcome of this study reflects the impact of Zaynich’s novel β-lactam enhancer mechanism of action. Additionally, Zaynich® was well-tolerated and showed a safety profile consistent with β-lactam class of antibiotics, comparable to meropenem.

This study is NDA-enabling, based on which marketing authorization applications will be made to global health authorities including India, US, EMA and MHRA. For India, the DCGI filing for commercial approval was submitted on 31st March 2025. In parallel, preparations for the U.S. New Drug Application (NDA) filing are progressing, marked by the successful completion of a pre-NDA meeting with the U.S. Food and Drug Administration (FDA). Filing in USA is expected by August 2025

Compassionate Use: We have treated 51 patients, including three US Patients, under compassionate use, after receiving approval from DCGI and US FDA. Use of Zaynich[®] resulted in >95% cure and was found

==> picture [192 x 100] intentionally omitted <==

to be safe even when administered up to 95 days.

Meropenem Resistance Clinical

Trial as well as several patients successfully treated under compassionate use in India and US, have reaffirmed the life-saving feature of Zaynich®

MIQNAF® NAFITHROMYCIN, approved and launched on May 27 2025, in India

Wockhardt proudly announces the launch of India’s First Indigenous Respiratory Antibiotic on

May 27 2025 - A Historic Step in the fight against Antimicrobial Resistance and a transformative moment in India’s Antibiotic Research landscape.

This breakthrough ends a wait of over 30 years for a new antibiotic in the macrolide class, at a time when the world faces an escalating antimicrobial resistance (AMR) crisis.

MIQNAF is specifically designed to target both typical and atypical pathogens, offering new hope against multi-drugresistant infections with its Ultra Short Course, three day oral therapy.

==> picture [75 x 64] intentionally omitted <==

==> picture [74 x 64] intentionally omitted <==

Approved for Community-Acquired Bacterial Pneumonia (CABP) caused by resistant Respiratory Pathogens, the drug addresses a leading global cause of death, which claims over 2 million lives annually.

Wockhardt Limited Registered Office: D-4, MIDC, Chikalthana Chhatrapati Sambhajinagar 431006, India Tel.: +91-22-2653 4444 CIN: L24230MH1999PLC120720

==> picture [143 x 30] intentionally omitted <==

==> picture [178 x 53] intentionally omitted <==

==> picture [154 x 38] intentionally omitted <==

With India carrying 23% of the world’s pneumonia burden, MIQNAF’s development comes as a critical solution to current treatment gaps and rising resistance to older antibiotics like azithromycin and co-amoxiclav.

==> picture [154 x 35] intentionally omitted <==

MIQNAF offers high safety and tolerability, with minimal gastrointestinal effects, no significant drug interactions, and no dietary restrictions.

==> picture [116 x 32] intentionally omitted <==

In India, MIQNAF is being strategically introduced to specialists, specifically chest physicians and consulting physicians. To support this targeted approach, a dedicated MIQNAF team has being established to engage with these medical professionals.

The journey of MIQNAF has spanned 14 years of rigorous research and development including clinical trials in the US, Europe, and India.

==> picture [117 x 92] intentionally omitted <==

Company won the prestigious BIRAC INNOVATOR AWARD 2024 from the Government of India for the highest level of innovation and research that lead to successful development of MIQNAF

MIQNAF launch signals India’s leadership in the global response to antimicrobial resistance.

Wockhardt plans to expand MIQNAF’s reach to Saudi Arabia, Latin America, Southeast Asia, and Africa in the near and midterm future.

ERTAPENEM-ZIDEBACTAM (WCK 6777) : WCK 6777 is a once-a-day, β-lactam enhancer-based combination being developed for outpatient parenteral antimicrobial therapy (OPAT) in ambulatory settings. WCK 6777 is the only drug in the global antibiotic pipeline designed for OPAT.

WCK 6777 is active against entire range of meropenem-resistant Gram-negative pathogens generally encountered in community as well as in hospital urinary tract infections (UTI) and intra-abdominal infections (IAI). Such a therapeutic option is expected to cut hospital admissions, facilitate early patient discharge and thus offer patient-centred care for MDR infections.

==> picture [176 x 66] intentionally omitted <==

Recognizing its potential to meet significant unmet medical needs, the US FDA has granted Fast Track designation to WCK 6777 for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, and complicated intra-abdominal infections (cIAI).

Results from Phase I study (52 subjects) conducted by National Institutes of Health, US, demonstrated a promising safety profile, with WCK 6777 being well-tolerated, and no serious

Wockhardt Limited Registered Office: D-4, MIDC, Chikalthana Chhatrapati Sambhajinagar 431006, India Tel.: +91-22-2653 4444 CIN: L24230MH1999PLC120720

==> picture [143 x 30] intentionally omitted <==

==> picture [178 x 53] intentionally omitted <==

or unexpected adverse events reported. This study paves the way for advancement of WCK 6777 into Phase II trial.

EMROK/ EMROK O : Emrok has successfully treated >100,000 patients to date. It is currently undergoing the registration process in 9 countries within emerging markets and anticipates receiving approvals within the next 6 to 12 months.

==> picture [179 x 51] intentionally omitted <==

Biosimilars Business Highlights:

==> picture [231 x 130] intentionally omitted <==

Our Insulin and Glargine business has demonstrated remarkable and sustainable growth driven by increasing volumes accelerating our presence and reach across Emerging Markets. Likewise in India, our domestic biotech business is poised for substantial growth. Upgradation and expansion of biosimilar facilities underway to meet existing

demand as well as our entry into newer emerging markets. This positions us well for scaling the Biotech business growth to the next level, strengthening our commitment to meeting global healthcare needs and advancing our leadership in diabetes care

Business Highlights

==> picture [234 x 108] intentionally omitted <==

==> picture [227 x 106] intentionally omitted <==

India Branded Business stood at Rs.95 crore in Q4FY25 and for FY25 the revenue was Rs. 456 crore.

UK Business stood at Rs.292 crore in Q4FY25 with a growth of 9% and for FY25 the revenue was Rs. 1,169 crore with a growth of 12%.

Irish Business stood at Rs.47 crore in Q4FY25 and for FY25 the revenue was Rs. 181 crore.

==> picture [143 x 30] intentionally omitted <==

==> picture [178 x 53] intentionally omitted <==

Wockhardt Limited Registered Office: D-4, MIDC, Chikalthana Chhatrapati Sambhajinagar 431006, India Tel.: +91-22-2653 4444 CIN: L24230MH1999PLC120720

New Products Launch FY’24-25:

• 7 Filings and 6 Launches in Wockhardt UK

• 1 Filing and 6 New launches in Ireland

• Biosimilars & NCE - 19 Filings & 5 Approvals

• EMROK/EMROK O - Registration

• has been filed in 9 countries of ROW & other Markets

==> picture [186 x 118] intentionally omitted <==

Intellectual Property Update:

• 4 patents were filed during the quarter ended 31[st ] March 2025 and the cumulative filings till date are 3273.

• The company was granted 4 patents during the quarter and now holds 848 patents.

• India - 6 NCE Patents Granted till Mar’25

==> picture [100 x 49] intentionally omitted <==

==> picture [103 x 35] intentionally omitted <==

Financial Performance:

Particulars	Q4 FY25	Q4 FY24	Q3 FY25 Oct - Dec 2024	FY25	FY24
	Jan - Mar 2025	Jan - Mar 2024		Apr - Mar 2025	Apr - Mar 2024
Total Revenue	743	750	725	3,033	2,879
EBITDA before R&D EBITDA % to Sales	113 15.2%	103 13.8%	131 18.1%	537 17.7%	384 13.3%
R&D R&D % to Sales	34 4.6%	33 4.4%	31 4.2%	119 3.9%	132 4.6%
EBITDA EBITDA Margins %	79 10.7%	70 9.4%	100 13.8%	418 13.8%	251 8.7%
Exceptional Items Loss on sale of property, plant & equipment #	- -	- (123)	- -	- -	(14) (131)
PBT	(22)	(180)	21	(16)	(420)
Profit After Tax PAT Margins %	(45) -6.1%	(177) -23.6%	20 2.8%	(57) -1.9%	(472) -16.4%

# In Q4FY24 and FY 24, the company had recognized an impairment loss of Rs. 79 crore on assets held for sale. Additionally, the company had incurred a loss of Rs. 42 crore on the sale of property, plant, and equipment attributable to the restructuring of the company's US operations.

==> picture [143 x 30] intentionally omitted <==

==> picture [178 x 53] intentionally omitted <==

Wockhardt Limited Registered Office: D-4, MIDC, Chikalthana Chhatrapati Sambhajinagar 431006, India Tel.: +91-22-2653 4444 CIN: L24230MH1999PLC120720

About Wockhardt

Wockhardt is a research based Global Pharmaceutical and Biotech company. Wockhardt’s New Drug Discovery programme has focussed on unmet need of Anti-bacterial drugs that are effective against the menace of untreatable superbugs. Wockhardt is the only company in the world where USFDA has given QIDP Status (Qualified Infectious Disease Product) for 6 of our Anti-bacterial discovery programmes – 3 of them are Gram Negative and 3 Gram Positive effective against untreatable “Superbugs”. It has a comprehensive Drug Discovery team and clinical organisation.

Wockhardt is employing around ~2900 people and 27 nationalities with presence in USA, UK, Ireland, Switzerland, France, Mexico, Russia and many other countries. It has manufacturing and research facilities in India, USA & UK and a manufacturing facility in Ireland. Wockhardt has a significant presence in USA, Europe and India, with 77% of its global revenues coming from international businesses.